Introduction: The use of the 5-alpha reductase inhibitors (5-ARIs) finasteride and dutasteride for prostate cancer prevention is still under debate. The FDA recently concluded that the increased prevalence of high-grade tumors among 5-ARI-treated patients must not be neglected, and they decided to disallow the use of 5-ARIs for prostate cancer prevention. This study was conducted to verify the effects of finasteride on prostate cell migration and invasion and the related enzymes/proteins in normal human and tumoral prostatic cell lines.Materials and Methods: RWPE-1, LNCaP, PC3 and DU145 cells were cultivated to 60% confluence and exposed for different periods to either 10 mu M or 50 mu M finasteride that was diluted in culture medium. The c...
Objective: To evaluate the effect of finasteride on serum androst-4-ene-3,17-dione (androstenedione)...
<p>The prostate cell lines were previously cultivated in 50 µM finasteride or control medium for 72 ...
The development and introduction in clinical practice of finasteride, the first potent inhibitor of ...
The use of the 5-alpha reductase inhibitors (5-ARIs) finasteride and dutasteride for prostate cancer...
The use of the 5-alpha reductase inhibitors (5-ARIs) finasteride and dutasteride for prostate cancer...
Introduction: The use of the 5-alpha reductase inhibitors (5-ARIs) finasteride and dutasteride for p...
P>The safety of using finasteride as a prevention of prostate cancer is still under debate. In this ...
BACKGROUND: Although finasteride is recognized for its role as a chemopreventive agent for prostate ...
Background: 5 alpha-reductase 1 (5alphaR1) and 5alpha-reductase 2 (5alphaR2) convert testosterone in...
5α-reductase 1 (5αR1) and 5α-reductase 2 (5αR2) convert testosterone into the more potent androgen d...
BACKGROUND: 5α-reductase 1 (5αR1) and 5α-reductase 2 (5αR2) convert testosterone into the more poten...
BackgroundIn the Prostate Cancer Prevention Trial, finasteride selectively suppressed low-grade pros...
AbstractBackgroundIn the Prostate Cancer Prevention Trial, finasteride selectively suppressed low-gr...
<p>The prostate cell lines were previously cultivated in 50 µM finasteride or control medium for 72 ...
Background: The prostate cancer prevention trial (PCPT) and Reduction by dutasteride of Prostate Can...
Objective: To evaluate the effect of finasteride on serum androst-4-ene-3,17-dione (androstenedione)...
<p>The prostate cell lines were previously cultivated in 50 µM finasteride or control medium for 72 ...
The development and introduction in clinical practice of finasteride, the first potent inhibitor of ...
The use of the 5-alpha reductase inhibitors (5-ARIs) finasteride and dutasteride for prostate cancer...
The use of the 5-alpha reductase inhibitors (5-ARIs) finasteride and dutasteride for prostate cancer...
Introduction: The use of the 5-alpha reductase inhibitors (5-ARIs) finasteride and dutasteride for p...
P>The safety of using finasteride as a prevention of prostate cancer is still under debate. In this ...
BACKGROUND: Although finasteride is recognized for its role as a chemopreventive agent for prostate ...
Background: 5 alpha-reductase 1 (5alphaR1) and 5alpha-reductase 2 (5alphaR2) convert testosterone in...
5α-reductase 1 (5αR1) and 5α-reductase 2 (5αR2) convert testosterone into the more potent androgen d...
BACKGROUND: 5α-reductase 1 (5αR1) and 5α-reductase 2 (5αR2) convert testosterone into the more poten...
BackgroundIn the Prostate Cancer Prevention Trial, finasteride selectively suppressed low-grade pros...
AbstractBackgroundIn the Prostate Cancer Prevention Trial, finasteride selectively suppressed low-gr...
<p>The prostate cell lines were previously cultivated in 50 µM finasteride or control medium for 72 ...
Background: The prostate cancer prevention trial (PCPT) and Reduction by dutasteride of Prostate Can...
Objective: To evaluate the effect of finasteride on serum androst-4-ene-3,17-dione (androstenedione)...
<p>The prostate cell lines were previously cultivated in 50 µM finasteride or control medium for 72 ...
The development and introduction in clinical practice of finasteride, the first potent inhibitor of ...